Adma Biologics ADMA

Nasdaq · Biological Products, (No Diagnostic Substances) · $3.1B
Every report since 2023 →

No closes on file for ADMA yet.

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$3.1B
EV / True FCF390.0x
Revenue$510.2M +19.6%
True FCF (ex-SBC)$7.8M −74.8%
Rule of 4025.1%
ROIC33.1%
True FCF Yield0.3%
EPS, diluted$0.60 −25.9%
Modern Valuation (EOD)
Market Cap$3.1B
Enterprise Value$3.0B
EV / True FCF390.02
EV / FCF109.28
EV / Gross Profit10.38
EV / EBIT15.88
EV / Sales5.96
P / E (GAAP)20.78
P / FCF109.73
P / Oper. CF60.58
P / Book6.40
Owner & Cash Yields
True FCF Yield0.3%
FCF Yield0.9%
Owner Earn. Yield3.7%
Earnings Yield4.8%
Shareholder Yield+0.4%
Buyback Yield1.0%
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$0.13
EPS (diluted)$0.60
Compounder & Returns
Rule of 4025.1%
ROIC33.1%
Cash ROIC (CROIC)6.0%
GP / Assets46.9%
ROE30.8%
ROA23.5%
Gross Margin57.4%
Oper. Margin37.5%
Net Margin28.8%
FCF Margin5.5%
True FCF Margin1.5%
Quality & Dilution
Cash Conversion19%
Accrual Ratio+15.5%
SBC % of FCF72.0%
SBC % of Rev3.9%
Reinvest. Rate54%
Sales Growth Y/Y+19.6%
Sales 3Y CAGR+49.0%
EPS Growth Y/Y−25.9%
FCF Growth Y/Y−74.8%
FCF 3Y CAGR—
Share Change Y/Y+0.6%
Balance Sheet & Scale
Revenue (FY)$510.2M
Gross Profit (FY)$292.8M
Oper. Income (FY)$191.4M
GAAP Net Income$146.9M
True FCF (ex-SBC)$7.8M
Cash & Equiv$87.6M
Total Debt$75.0M
Net Cash (Debt)$12.7M
Net Cash % MCap+0.4%
Debt / FCF (yrs)2.7y
Current Ratio6.71221.85M sh
Price & Technicals (EOD)
Perf Week—
Perf Month—
Perf Quarter—
Perf Half Y—
Perf YTD—
SMA 20 Dist—
SMA 50 Dist—
SMA 100 Dist—
Window High—
Window Low—
RSI (14) · Vol—
Income Distribution & Cash Flow ConversionHow every dollar of ADMA revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%$510.2MGROSS PROFIT · 57.4%$292.8MCOST OF REV · 42.6%$217.4MOPER. INCOME · 37.5%$191.4MOPEX · 19.9%R&D $4.8M · SG&A $91.6MNET INCOME · 28.8%$146.9MTAX & OTHER · 8.7%$44.5M
Where Every $100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)$217.4M ($42.6 / $100)
R&D Reinvestment$4.8M ($0.9 / $100)
SG&A & Other OpEx$96.6M ($18.9 / $100)
Tax & Non-Operating$44.5M ($8.7 / $100)
Net Profit Kept$146.9M ($28.8 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Income$146.9M (28.8% margin)
Operating Cash Flow (OCF)$50.4M(9.9% of rev)
Less: Capital Expenditures−$22.6M(4.4% of rev)
Standard Free Cash Flow (FCF)$27.8M(5.5% margin)
Less: Stock-Based Comp (SBC)−$20.0M(72.0% of FCF)
True FCF (Owner Cash ex-SBC)$7.8M(1.5% of rev)

Operating leverage — margins

GrossOperatingNet
0%40%80%57%38%29%FY21FY22FY23FY24FY25
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)FY2021FY2022FY2023FY2024FY2025YoY Δ4Y CAGRTrend
Income Statement
Cost of Revenue (COGS)$79.8M$118.8M$169.3M$206.9M$217.4M+5.1%+28.5%
Research & Development (R&D)$3.6M$3.6M$3.3M$1.8M$4.8M+162.7%+6.9%
Selling, General & Admin (SG&A)$42.9M$52.5M$59.0M$74.1M$91.6M+23.5%+20.9%
Total Operating Expenses$59.5M$74.6M$67.3M$80.6M$101.3M+25.8%+14.2%
Interest Expense$13.1M$19.3M$25.0M$13.9M$7.1M−49.0%−14.1%
Income Tax Expense$0$0$0$-72.0M$35.7M+149.6%—
Diluted Shares139.6M197.9M224.0M243.3M244.9M+0.6%+15.1%
Balance Sheet
Cash & Equivalents$51.1M$86.5M$51.4M$103.1M$87.6M−15.0%+14.4%
Inventory$124.7M$163.3M$172.9M$170.2M$206.5M+21.3%+13.4%
Total Current Assets$208.7M$270.4M$257.0M$331.4M$466.5M+40.8%+22.3%
Total Assets$276.3M$348.5M$329.2M$488.7M$624.2M+27.7%+22.6%
Total Current Liabilities$30.4M$39.3M$49.8M$55.5M$69.5M+25.2%+23.0%
Total Debt (Short + Long Term)$4.2M$4.2M$4.2M$72.3M$75.0M+3.6%+105.3%
Total Liabilities$135.1M$196.5M$194.0M$139.7M$146.9M+5.2%+2.1%
Stockholders' Equity$141.2M$152.0M$135.2M$349.0M$477.3M+36.8%+35.6%
Net Cash / (Net Debt)$46.9M$82.3M$47.1M$30.8M$12.7M−58.9%−27.9%
Invested Capital$94.3M$69.7M$88.1M$318.2M$464.6M+46.0%+49.0%
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)$4.8M$6.4M$7.6M$7.7M$8.0M+3.9%+13.6%
Stock-Based Compensation (SBC)$3.5M$5.2M$6.2M$13.6M$20.0M+47.1%+54.8%
Capital Expenditures (CapEx)$13.5M$13.9M$4.8M$8.2M$22.6M+174.4%+13.7%
True FCF (ex-SBC Owner Cash)$-129.4M$-78.6M$-2.2M$96.8M$7.8M−91.9%—
Share Repurchases (Buybacks)——$0$0$31.9M——

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what ADMA did at the next close after each story
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.